Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -257,590 | -197,651 | -131,358 | -65,000 | -327,265 |
| Depreciation Amortization | 5,291 | 3,709 | 2,201 | 758 | 7,390 |
| Accounts payable and accrued liabilities | -503 | -537 | 6,690 | -118 | -7,502 |
| Other Working Capital | -24,799 | -30,069 | -24,036 | -5,650 | -21,307 |
| Other Operating Activity | 77,301 | 60,946 | 27,016 | 14,111 | 110,951 |
| Operating Cash Flow | $-200,300 | $-163,602 | $-119,487 | $-55,899 | $-237,733 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -694 | -437 | -8 | -8 | -1,516 |
| Purchase Of Investment | -361,475 | -314,501 | -123,739 | -81,131 | -438,629 |
| Sale Of Investment | 437,857 | 335,692 | 220,493 | 103,272 | 603,434 |
| Investing Cash Flow | $75,688 | $20,754 | $96,746 | $22,133 | $163,289 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 114,395 | 108,652 | 107,973 | 1,650 | 95,695 |
| Other Financing Activity | 2,280 | 2,280 | 2,280 | 0 | 0 |
| Financing Cash Flow | $116,675 | $110,932 | $110,253 | $1,650 | $95,695 |
| Beginning Cash Position | 93,447 | 93,447 | 93,447 | 93,447 | 72,196 |
| End Cash Position | 85,510 | 61,531 | 180,959 | 61,331 | 93,447 |
| Net Cash Flow | $-7,937 | $-31,916 | $87,512 | $-32,116 | $21,251 |
| Free Cash Flow | |||||
| Operating Cash Flow | -200,300 | -163,602 | -119,487 | -55,899 | -237,733 |
| Capital Expenditure | -694 | -437 | -8 | -8 | -1,516 |
| Free Cash Flow | -200,994 | -164,039 | -119,495 | -55,907 | -239,249 |